[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI0703228T1 - Naphthyl compounds, intermediates, processes, compositions involving them - Google Patents

Naphthyl compounds, intermediates, processes, compositions involving them

Info

Publication number
SI0703228T1
SI0703228T1 SI9530587T SI9530587T SI0703228T1 SI 0703228 T1 SI0703228 T1 SI 0703228T1 SI 9530587 T SI9530587 T SI 9530587T SI 9530587 T SI9530587 T SI 9530587T SI 0703228 T1 SI0703228 T1 SI 0703228T1
Authority
SI
Slovenia
Prior art keywords
alkyl
pyrrolidinyl
intermediates
processes
compositions involving
Prior art date
Application number
SI9530587T
Other languages
English (en)
Slovenian (sl)
Inventor
Henry Uhlmann Bryant
George Joseph Cullinan
Jeffrey Alan Dodge
Kennan Joseph Fahey
Charles David Jones
Iii Charles Willis Lugar
Brian Stephen Muehl
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI0703228T1 publication Critical patent/SI0703228T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Silicon Polymers (AREA)
SI9530587T 1994-09-20 1995-09-18 Naphthyl compounds, intermediates, processes, compositions involving them SI0703228T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/309,525 US7501441B1 (en) 1994-09-20 1994-09-20 Naphthyl compounds, intermediates, processes, compositions, and methods
EP95306549A EP0703228B1 (de) 1994-09-20 1995-09-18 Naphthyl-Derivate, Zwischenprodukte, Verfahren, Zusammensetzungen, die sie enthalten

Publications (1)

Publication Number Publication Date
SI0703228T1 true SI0703228T1 (en) 2002-08-31

Family

ID=23198583

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530587T SI0703228T1 (en) 1994-09-20 1995-09-18 Naphthyl compounds, intermediates, processes, compositions involving them

Country Status (29)

Country Link
US (6) US7501441B1 (de)
EP (1) EP0703228B1 (de)
JP (1) JPH10506392A (de)
KR (1) KR970705983A (de)
AT (1) ATE214058T1 (de)
AU (1) AU697114B2 (de)
BR (1) BR9508967A (de)
CA (1) CA2200449A1 (de)
CO (1) CO4410318A1 (de)
CZ (1) CZ291207B6 (de)
DE (1) DE69525699T2 (de)
DK (1) DK0703228T3 (de)
ES (1) ES2173154T3 (de)
HU (1) HUT77919A (de)
IL (1) IL115335A (de)
MX (1) MX9702154A (de)
MY (1) MY132075A (de)
NO (1) NO307929B1 (de)
NZ (1) NZ294177A (de)
PE (1) PE47496A1 (de)
PL (1) PL319454A1 (de)
PT (1) PT703228E (de)
RU (1) RU2165924C2 (de)
SI (1) SI0703228T1 (de)
TR (1) TR199501135A2 (de)
TW (1) TW399036B (de)
WO (1) WO1996009039A1 (de)
YU (1) YU61595A (de)
ZA (1) ZA957857B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US6451817B1 (en) * 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
US6391892B1 (en) * 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
GB2312844A (en) * 1996-05-07 1997-11-12 Lilly Co Eli A naphthyl compound for the treatment of immune-complex diseases
CA2213814A1 (en) * 1996-08-29 1998-02-28 Henry Uhlman Bryant Naphthalene compounds, intermediates, formulations, and methods
CA2214070C (en) * 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
US6599920B2 (en) * 1996-08-29 2003-07-29 Eli Lilly And Company Naphthalene compounds, intermediates, formulations, and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
SI0826679T1 (en) * 1996-08-29 2002-04-30 Eli Lilly And Company Naphthyl compounds and compositions
CA2214931A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorene compounds and method of use
CA2214196A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Benzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods
CA2215856A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Dihydrobenzofluorene compounds, intermediates, compositions, and methods
CA2214929A1 (en) * 1996-09-26 1998-03-26 Charles Willis Lugar, Iii Naphthofluorene compounds, intermediates, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2214872C (en) * 1996-10-24 2002-01-22 Eli Lilly And Company Benzothiophene compounds, compositions and methods
CA2216592C (en) * 1996-10-24 2006-07-18 Brian Stephen Muehl Benzothiophene compounds, intermediates, compositions, and methods
CA2215647A1 (en) * 1996-10-24 1998-04-24 Eli Lilly And Company Naphthyl compounds, compositions, and methods
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
IT1298159B1 (it) * 1997-01-28 1999-12-20 Hoffmann La Roche Derivati di un 5-aroilnaftalene
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO1998048806A1 (en) * 1997-04-25 1998-11-05 Eli Lilly And Company Indene compounds having activity as serms
US6509356B1 (en) 1997-08-07 2003-01-21 Eli Lilly And Company 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity
US6090843A (en) * 1997-08-11 2000-07-18 Eli Lilly And Company Benzothiophenes compounds which have useful pharmaceutical activity
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US5834488A (en) * 1997-09-19 1998-11-10 Eli Lilly And Company Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
DE69822861T2 (de) 1997-10-03 2005-01-27 Eli Lilly And Co., Indianapolis Bentzothiophene
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
ATE321754T1 (de) 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
WO2002094268A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
ES2326593T3 (es) 2002-07-22 2009-10-15 Eli Lilly And Company Moduladores de receptores de estrogeno selectivos que contienen un grupo fenilsulfonilo.
EP1601356A1 (de) 2003-02-25 2005-12-07 Eli Lilly and Company Kristallines nicht solvatisiertes 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalenhydrochlorid
EA007978B1 (ru) * 2003-02-25 2007-02-27 Эли Лилли Энд Компани Кристаллический несольватированный гидрохлорид 1-(4-(2-пиперидинилэтокси)фенокси)-2-(4-метансульфонилфенил)-6-гидроксинафталина
US20060167051A1 (en) * 2003-02-25 2006-07-27 Remick David M Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
ATE515493T1 (de) * 2003-03-31 2011-07-15 Council Scient Ind Res Mercaptophenylnaphthylmethan-derivate und deren herstellung
EP1667692A1 (de) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmazeutische zusammensetzungen mit kombinationen von 2-alkyliden-19-nor-vitamin d derivaten und einem östrogen-agonisten/antagonisten
KR20060109926A (ko) 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
MXPA06006810A (es) * 2003-12-17 2006-08-23 Pfizer Prod Inc Tratamiento de afecciones que se presentan con un nivel bajo de masa osea por terapia de combinacion continua con agonistas selectivos del receptor de prostaglandina ep4 y un estrogeno.
EP1709023B1 (de) 2004-01-22 2009-11-11 Eli Lilly And Company Selektive östrogen-rezeptor-modulatoren
WO2005073205A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
JP2007528408A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
BRPI0518300A2 (pt) * 2004-11-23 2008-11-11 Warner Lambert Co derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
ES2354267T3 (es) * 2005-02-09 2011-03-11 Arqule, Inc. Derivados de maleimida, composiciones farmacéuticas y métodos para el tratamiento del cáncer.
US7655700B2 (en) 2005-08-25 2010-02-02 Michigan State University Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
EP2342189A2 (de) * 2008-09-29 2011-07-13 Eli Lilly And Company Selektiver östrogenrezeptormodulator zur behandlung von osteoarthritis
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
KR101731008B1 (ko) 2010-06-16 2017-04-27 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
MX2020008680A (es) 2018-02-21 2020-09-25 Ai Therapeutics Inc Terapia de combinacion con apilimod y agentes glutamatergicos.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3396169A (en) 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
FR90418E (fr) * 1962-09-13 1967-12-08 Ici Ltd Nouveaux dérivés alkéniques
US3862232A (en) 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3313853A (en) 1963-10-16 1967-04-11 Upjohn Co 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones
US3293263A (en) 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3320271A (en) 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
DE1300575B (de) 1965-05-21 1969-08-07 Bristol Myers Co Benzo[b]thiophene
US3394125A (en) 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US3483293A (en) 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3567737A (en) 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
IL45454A (en) * 1973-08-31 1977-06-30 Ciba Geigy Ag 3-methyl-4-(p-phenoxy(or benzyl)-phenoxy)-2-butene derivatives their preparation and pest-population contaol compositions containing them
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
AU555658B2 (en) * 1981-04-03 1986-10-02 Eli Lilly And Company Benzothiophene compounds
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8311678D0 (en) 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
FR2599031B1 (fr) * 1986-05-23 1988-07-22 Oreal Nouveaux composes naphtyl aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
US4859695A (en) * 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
US4851554A (en) * 1987-04-06 1989-07-25 University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4122484A1 (de) 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives

Also Published As

Publication number Publication date
EP0703228A1 (de) 1996-03-27
PE47496A1 (es) 1996-11-12
CO4410318A1 (es) 1997-01-09
IL115335A (en) 2000-07-26
ES2173154T3 (es) 2002-10-16
KR970705983A (ko) 1997-11-03
PL319454A1 (en) 1997-08-04
TR199501135A2 (tr) 1996-06-21
US5484797A (en) 1996-01-16
NO307929B1 (no) 2000-06-19
JPH10506392A (ja) 1998-06-23
DE69525699T2 (de) 2002-11-21
CZ291207B6 (cs) 2003-01-15
DE69525699D1 (de) 2002-04-11
TW399036B (en) 2000-07-21
AU3686395A (en) 1996-04-09
YU61595A (sh) 1998-09-18
WO1996009039A1 (en) 1996-03-28
US7501441B1 (en) 2009-03-10
MY132075A (en) 2007-09-28
ATE214058T1 (de) 2002-03-15
NO971278D0 (no) 1997-03-19
CA2200449A1 (en) 1996-03-28
RU2165924C2 (ru) 2001-04-27
US5484796A (en) 1996-01-16
HUT77919A (hu) 1998-10-28
US5484795A (en) 1996-01-16
PT703228E (pt) 2002-07-31
US6410564B1 (en) 2002-06-25
NZ294177A (en) 1998-10-28
IL115335A0 (en) 1995-12-31
MX9702154A (es) 1997-06-28
EP0703228B1 (de) 2002-03-06
ZA957857B (en) 1997-03-18
US6437137B1 (en) 2002-08-20
AU697114B2 (en) 1998-09-24
BR9508967A (pt) 1997-12-30
CZ82297A3 (en) 1997-12-17
DK0703228T3 (da) 2002-05-21
NO971278L (no) 1997-05-14

Similar Documents

Publication Publication Date Title
SI0703228T1 (en) Naphthyl compounds, intermediates, processes, compositions involving them
MX9600743A (es) Compuestos de naftilo, intermediarios y composiciones farmaceuticas a partir de los mismos y proceso para su preparacion.
GEP20084496B (en) Benzothiophene compound, intermediate, composition, and method
BR9609844A (pt) Intermediários de daftila e dihidronaftila compostos composições e processos
ATE207473T1 (de) Dihydronaphthalen- und naphthalenderivate, zwischenverbindungen, zusammensetzungen und deren herstellungsverfahren
DE69532079D1 (de) Benzofuranverbindungen, präparate und verfahren
DE69726513D1 (de) Benzo[B]thiophenverbindungen,Zwischenprodukte,Verfahren,Zusammensetzungen und Methode
AU3686295A (en) A method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
PT832881E (pt) Compostos de benzofluoreno intermediarios composicoes e metodos
CA2170479A1 (en) Benzothiophene compounds, intermediates, compositions, and methods
RS49886B (sr) Benzotiofenska jedinjenja, intermedijari, kompozicije i metode
TW349096B (en) Benzothiophene compounds, intermediates, compositions, and methods